Skip to content

TriangleGet started

← Full study record

NCT03735121 · OUTCOME

Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Source last updated 2025-12-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64 (Cycle length = 21 days)

What was measured

The overall patient-reported AE burden was assessed using a single item from the EORTC IL57 questionnaire i.e "To what extent have you been troubled with side-effects from your treatment?" The questions were answered on a 4-point Likert scale, where 1="Not at all" to 4="Very much". Higher scores indicated greater AE burden. Percentages have been rounded to one decimal place.

Analysis population: FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

Groups in this outcome

Part 2: Atezolizumab IV 1200 mg

Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.

Part 2: Atezolizumab SC 1875 mg

Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	113
Part 2: Atezolizumab SC 1875 mg	238

Reported measurements

Baseline - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	113
Part 2: Atezolizumab SC 1875 mg	238

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	49.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	56.7	Not reported	Not reported	Not reported	Not reported

Baseline - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	113
Part 2: Atezolizumab SC 1875 mg	238

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	36.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	28.6	Not reported	Not reported	Not reported	Not reported

Baseline - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	113
Part 2: Atezolizumab SC 1875 mg	238

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	8.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	10.1	Not reported	Not reported	Not reported	Not reported

Baseline - Very much

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	113
Part 2: Atezolizumab SC 1875 mg	238

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	6.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	4.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 2 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	108
Part 2: Atezolizumab SC 1875 mg	222

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	47.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	49.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 2 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	108
Part 2: Atezolizumab SC 1875 mg	222

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	39.8	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	35.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 2 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	108
Part 2: Atezolizumab SC 1875 mg	222

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	9.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	12.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 2 - Very much

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	108
Part 2: Atezolizumab SC 1875 mg	222

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	3.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	2.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 3 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	88
Part 2: Atezolizumab SC 1875 mg	184

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	43.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	46.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 3 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	88
Part 2: Atezolizumab SC 1875 mg	184

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	45.5	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	41.8	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 3 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	88
Part 2: Atezolizumab SC 1875 mg	184

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	10.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	8.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 3 - Very much

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	88
Part 2: Atezolizumab SC 1875 mg	184

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	1.1	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	2.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 4 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	82
Part 2: Atezolizumab SC 1875 mg	169

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	48.8	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	46.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 4 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	82
Part 2: Atezolizumab SC 1875 mg	169

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	36.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	36.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 4 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	82
Part 2: Atezolizumab SC 1875 mg	169

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	14.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	15.4	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 4 - Very much

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	82
Part 2: Atezolizumab SC 1875 mg	169

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	1.8	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 5 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	64
Part 2: Atezolizumab SC 1875 mg	136

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	56.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	55.9	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 5 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	64
Part 2: Atezolizumab SC 1875 mg	136

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	35.9	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	36.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 5 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	64
Part 2: Atezolizumab SC 1875 mg	136

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	7.8	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	5.9	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 5 - Very much

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	64
Part 2: Atezolizumab SC 1875 mg	136

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	2.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 6 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	59
Part 2: Atezolizumab SC 1875 mg	122

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	54.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	49.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 6 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	59
Part 2: Atezolizumab SC 1875 mg	122

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	37.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	40.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 6 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	59
Part 2: Atezolizumab SC 1875 mg	122

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	8.5	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	8.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 6 - Very much

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	59
Part 2: Atezolizumab SC 1875 mg	122

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	2.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 8 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	48
Part 2: Atezolizumab SC 1875 mg	96

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	62.5	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	58.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 8 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	48
Part 2: Atezolizumab SC 1875 mg	96

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	33.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	37.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 8 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	48
Part 2: Atezolizumab SC 1875 mg	96

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	4.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	4.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 10 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	42
Part 2: Atezolizumab SC 1875 mg	81

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	66.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	54.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 10 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	42
Part 2: Atezolizumab SC 1875 mg	81

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	28.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	44.4	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 10 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	42
Part 2: Atezolizumab SC 1875 mg	81

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	4.8	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	1.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 12 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	36
Part 2: Atezolizumab SC 1875 mg	70

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	63.9	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	50.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 12 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	36
Part 2: Atezolizumab SC 1875 mg	70

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	30.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	45.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 12 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	36
Part 2: Atezolizumab SC 1875 mg	70

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	5.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	4.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 14 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	31
Part 2: Atezolizumab SC 1875 mg	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	61.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	53.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 14 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	31
Part 2: Atezolizumab SC 1875 mg	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	25.8	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	45.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 14 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	31
Part 2: Atezolizumab SC 1875 mg	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	12.9	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	1.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 16 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	28
Part 2: Atezolizumab SC 1875 mg	53

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	60.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	56.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 16 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	28
Part 2: Atezolizumab SC 1875 mg	53

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	28.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	35.8	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 16 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	28
Part 2: Atezolizumab SC 1875 mg	53

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	10.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	7.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 18 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	23
Part 2: Atezolizumab SC 1875 mg	50

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	69.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	58.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 18 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	23
Part 2: Atezolizumab SC 1875 mg	50

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	30.4	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	36.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 18 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	23
Part 2: Atezolizumab SC 1875 mg	50

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	6.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 20 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	21
Part 2: Atezolizumab SC 1875 mg	44

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	71.4	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	59.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 20 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	21
Part 2: Atezolizumab SC 1875 mg	44

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	28.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	31.8	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 20 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	21
Part 2: Atezolizumab SC 1875 mg	44

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	9.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 22 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	18
Part 2: Atezolizumab SC 1875 mg	36

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	55.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	52.8	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 22 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	18
Part 2: Atezolizumab SC 1875 mg	36

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	38.9	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	36.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 22 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	18
Part 2: Atezolizumab SC 1875 mg	36

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	5.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	11.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 24 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	16
Part 2: Atezolizumab SC 1875 mg	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	75.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	55.9	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 24 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	16
Part 2: Atezolizumab SC 1875 mg	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	25.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	38.2	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 24 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	16
Part 2: Atezolizumab SC 1875 mg	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	5.9	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 26 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	15
Part 2: Atezolizumab SC 1875 mg	31

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	73.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	51.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 26 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	15
Part 2: Atezolizumab SC 1875 mg	31

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	26.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	41.9	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 26 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	15
Part 2: Atezolizumab SC 1875 mg	31

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	6.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 28 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	14
Part 2: Atezolizumab SC 1875 mg	23

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	64.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	56.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 28 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	14
Part 2: Atezolizumab SC 1875 mg	23

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	35.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	39.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 28 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	14
Part 2: Atezolizumab SC 1875 mg	23

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	4.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 30 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	13
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	69.2	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	70.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 30 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	13
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	30.8	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	25.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 30 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	13
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	5.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 32 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	12
Part 2: Atezolizumab SC 1875 mg	22

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	50.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	59.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 32 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	12
Part 2: Atezolizumab SC 1875 mg	22

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	41.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	36.4	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 32 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	12
Part 2: Atezolizumab SC 1875 mg	22

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	8.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	4.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 34 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	72.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	65.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 34 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	27.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	35.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 36 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	63.6	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	65.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 36 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	20

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	36.4	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	35.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 38 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	72.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	61.1	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 38 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	27.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	33.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 38 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	5.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 40 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	72.7	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	55.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 40 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	27.3	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	38.9	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 40 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	11
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	5.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 42 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	75.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	66.7	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 42 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	18

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	25.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	33.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 44 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	16

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	75.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	68.8	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 44 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	16

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	25.0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	31.3	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 46 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	17

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	87.5	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	76.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 46 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	17

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	23.5	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 46 - Quite a bit

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	8
Part 2: Atezolizumab SC 1875 mg	17

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	12.5	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 48 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	7
Part 2: Atezolizumab SC 1875 mg	14

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	71.4	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 48 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	7
Part 2: Atezolizumab SC 1875 mg	14

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	28.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 50 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	7
Part 2: Atezolizumab SC 1875 mg	11

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	63.6	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 50 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	7
Part 2: Atezolizumab SC 1875 mg	11

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	36.4	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 52 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	6
Part 2: Atezolizumab SC 1875 mg	10

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	60.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 52 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	6
Part 2: Atezolizumab SC 1875 mg	10

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	40.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 54 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	3
Part 2: Atezolizumab SC 1875 mg	8

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	50.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 54 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	3
Part 2: Atezolizumab SC 1875 mg	8

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	50.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 56 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	2
Part 2: Atezolizumab SC 1875 mg	3

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 56 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	2
Part 2: Atezolizumab SC 1875 mg	3

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	100	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 58 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	1
Part 2: Atezolizumab SC 1875 mg	2

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	50.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 58 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	1
Part 2: Atezolizumab SC 1875 mg	2

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	50.0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 60 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	1
Part 2: Atezolizumab SC 1875 mg	1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 60 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	1
Part 2: Atezolizumab SC 1875 mg	1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	100	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 62 - Not at all

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	1
Part 2: Atezolizumab SC 1875 mg	1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	100	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	0	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 62 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	1
Part 2: Atezolizumab SC 1875 mg	1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab IV 1200 mg	0	Not reported	Not reported	Not reported	Not reported
Part 2: Atezolizumab SC 1875 mg	100	Not reported	Not reported	Not reported	Not reported

Day 1 Cycle 64 - A little

Analysis denominator · Participants

Group	Source count
Part 2: Atezolizumab IV 1200 mg	0
Part 2: Atezolizumab SC 1875 mg	1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Part 2: Atezolizumab SC 1875 mg	100	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
49.6
group Id
OG001
value
56.7
denoms
counts
group Id
OG000
value
113
group Id
OG001
value
238
units
Participants
title
Baseline - Not at all
categories
measurements
group Id
OG000
value
36.3
group Id
OG001
value
28.6
denoms
counts
group Id
OG000
value
113
group Id
OG001
value
238
units
Participants
title
Baseline - A little
categories
measurements
group Id
OG000
value
8.0
group Id
OG001
value
10.1
denoms
counts
group Id
OG000
value
113
group Id
OG001
value
238
units
Participants
title
Baseline - Quite a bit
categories
measurements
group Id
OG000
value
6.2
group Id
OG001
value
4.6
denoms
counts
group Id
OG000
value
113
group Id
OG001
value
238
units
Participants
title
Baseline - Very much
categories
measurements
group Id
OG000
value
47.2
group Id
OG001
value
49.5
denoms
counts
group Id
OG000
value
108
group Id
OG001
value
222
units
Participants
title
Day 1 Cycle 2 - Not at all
categories
measurements
group Id
OG000
value
39.8
group Id
OG001
value
35.6
denoms
counts
group Id
OG000
value
108
group Id
OG001
value
222
units
Participants
title
Day 1 Cycle 2 - A little
categories
measurements
group Id
OG000
value
9.3
group Id
OG001
value
12.6
denoms
counts
group Id
OG000
value
108
group Id
OG001
value
222
units
Participants
title
Day 1 Cycle 2 - Quite a bit
categories
measurements
group Id
OG000
value
3.7
group Id
OG001
value
2.3
denoms
counts
group Id
OG000
value
108
group Id
OG001
value
222
units
Participants
title
Day 1 Cycle 2 - Very much
categories
measurements
group Id
OG000
value
43.2
group Id
OG001
value
46.7
denoms
counts
group Id
OG000
value
88
group Id
OG001
value
184
units
Participants
title
Day 1 Cycle 3 - Not at all
categories
measurements
group Id
OG000
value
45.5
group Id
OG001
value
41.8
denoms
counts
group Id
OG000
value
88
group Id
OG001
value
184
units
Participants
title
Day 1 Cycle 3 - A little
categories
measurements
group Id
OG000
value
10.2
group Id
OG001
value
8.7
denoms
counts
group Id
OG000
value
88
group Id
OG001
value
184
units
Participants
title
Day 1 Cycle 3 - Quite a bit
categories
measurements
group Id
OG000
value
1.1
group Id
OG001
value
2.7
denoms
counts
group Id
OG000
value
88
group Id
OG001
value
184
units
Participants
title
Day 1 Cycle 3 - Very much

denoms

counts
group Id
OG000
value
113
group Id
OG001
value
238
units
Participants

description

The overall patient-reported AE burden was assessed using a single item from the EORTC IL57 questionnaire i.e "To what extent have you been troubled with side-effects from your treatment?" The questions were answered on a 4-point Likert scale, where 1="Not at all" to 4="Very much". Higher scores indicated greater AE burden. Percentages have been rounded to one decimal place.

groups

description
Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
id
OG000
title
Part 2: Atezolizumab IV 1200 mg
description
Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.
id
OG001
title
Part 2: Atezolizumab SC 1875 mg

param Type

NUMBER

population Description

FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

reporting Status

POSTED

time Frame

Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64 (Cycle length = 21 days)

title

Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice